JP2023022328A5 - - Google Patents

Info

Publication number

JP2023022328A5

JP2023022328A5 JP2022197804A JP2022197804A JP2023022328A5 JP 2023022328 A5 JP2023022328 A5 JP 2023022328A5 JP 2022197804 A JP2022197804 A JP 2022197804A JP 2022197804 A JP2022197804 A JP 2022197804A JP 2023022328 A5 JP2023022328 A5 JP 2023022328A5

Authority

JP

Japan

Prior art keywords

seq

amino acid

acid sequence

chain variable

variable region

Prior art date

2022-12-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims 170
• 239000000427 antigen Substances 0.000 claims 21
• 102000036639 antigens Human genes 0.000 claims 21
• 108091007433 antigens Proteins 0.000 claims 21
• 239000008194 pharmaceutical composition Substances 0.000 claims 10
• 239000000203 mixture Substances 0.000 claims 9
• 206010028980 Neoplasm Diseases 0.000 claims 5
• 229940079593 drug Drugs 0.000 claims 4
• 239000003814 drug Substances 0.000 claims 4
• 102100036466 Delta-like protein 3 Human genes 0.000 claims 2
• 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 2
• 206010041067 Small cell lung cancer Diseases 0.000 claims 2
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
• 238000011374 additional therapy Methods 0.000 claims 2
• 229940049706 benzodiazepine Drugs 0.000 claims 2
• 229940127276 delta-like ligand 3 Drugs 0.000 claims 2
• 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
• 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
• 239000012624 DNA alkylating agent Substances 0.000 claims 1
• 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
• 239000012661 PARP inhibitor Substances 0.000 claims 1
• 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 1
• 206010060862 Prostate cancer Diseases 0.000 claims 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
• 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
• 239000000611 antibody drug conjugate Substances 0.000 claims 1
• 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 108010044540 auristatin Proteins 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 229960002173 citrulline Drugs 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 1
• 230000005855 radiation Effects 0.000 claims 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
• 230000004614 tumor growth Effects 0.000 claims 1